Patents by Inventor Bo Niklasson
Bo Niklasson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220273624Abstract: The present invention relates to a combination of a picornaviridae capsid binding anti-viral agent and at least one further anti-viral agent for use in a method for treatment of a picornavirales infection in a mammalian subject comprising administering said combination to said mammalian subject. It further relates to an anti-viral agent for use in a method for 5 treatment of a picornavirales infection in a mammalian subject comprising administering said anti-viral agent to said mammalian subject, wherein the picornavirales infection is caused by a virus causing in vivo-expression of a VP1-protein detectable in infected tissue through immunohistochemical staining using an antibody raised against the VP1-protein of Ljungan virus, while said virus is not detectable in said infected tissue using a PCR assay 10 adapted for detection of Ljungan virus, as well as a pharmaceutical composition comprising Ljungan virus VP1 protein and a pharmaceutically acceptable adjuvant.Type: ApplicationFiled: April 22, 2020Publication date: September 1, 2022Inventor: Bo NIKLASSON
-
Patent number: 9044549Abstract: A syringe dispenser may include a plunger having an outer threading, a barrel adapted to contain liquid or semisolid fluid or any other material to be dispensed and to receive the plunger, the plunger being movably attached to the barrel, and a nut having an inner threading. The nut may at least partly enclose the plunger and the barrel, such that the inner threading of the nut engages with the outer threading of the plunger. A stand, an application plate, and a method of dispensing a controlled and measurable amount of liquid or semisolid fluid from a syringe dispenser are also disclosed.Type: GrantFiled: April 19, 2011Date of Patent: June 2, 2015Assignee: NOVISCENS ABInventor: Bo Niklasson
-
Publication number: 20130043282Abstract: A syringe dispenser may include a plunger having an outer threading, a barrel adapted to contain liquid or semisolid fluid or any other material to be dispensed and to receive the plunger, the plunger being movably attached to the barrel, and a nut having an inner threading. The nut may at least partly enclose the plunger and the barrel, such that the inner threading of the nut engages with the outer threading of the plunger. A stand, an application plate, and a method of dispensing a controlled and measurable amount of liquid or semisolid fluid from a syringe dispenser are also disclosed.Type: ApplicationFiled: April 19, 2011Publication date: February 21, 2013Applicant: NOVISCENS ABInventor: Bo Niklasson
-
Patent number: 8231879Abstract: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barre Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal.Type: GrantFiled: June 23, 2008Date of Patent: July 31, 2012Inventor: Bo Niklasson
-
Publication number: 20120027776Abstract: An isolated nucleic acid molecule is disclosed, including a nucleotide sequence selected from the nucleotide sequence of (a) Ljungan virus 87-012, (b) Ljungan virus 145SL, (c) Ljungan virus 174F, and (d) a fragment of nucleotide sequences (a)-(c). Also disclosed are polypeptides encoded by the isolated nucleic acid, which are useful in preparing vaccines and antibodies to prevent or inhibit conditions caused by Ljungan virus, including diabetes.Type: ApplicationFiled: June 1, 2009Publication date: February 2, 2012Inventors: Bo Niklasson, Ake Lernmark
-
Publication number: 20110300149Abstract: The present invention relates to a new group of Ljungan viruses, proteins expressed by the viruses, antibodies to the viruses and proteins, vaccines against the viruses, diagnostic kits for detecting the viruses, uses of the viruses, proteins, antibodies and vaccines in therapy, uses of the viruses, proteins, antibodies and vaccines in treating diseases caused by the viruses and methods of treatment for treating diseases caused by the viruses.Type: ApplicationFiled: December 23, 2009Publication date: December 8, 2011Applicant: Apodemus ABInventors: Bo Niklasson, Conny Tolf, Michael Lindberg
-
Publication number: 20110033418Abstract: A method of prophylactic and/or therapeutic treatment of a mammal is provided for treating a disease that is caused by a Ljungan virus infection. The method comprises administration to the mammal of an antivirally effective amount of ribavirin or a derivative thereof effective against the Ljungan virus and pleconaril or a derivative thereof effective against the Ljungan virus to eliminate or inhibit proliferation of said virus in said mammal and at the same time prevent and/or treat said disease in said mammal. Also provided is a composition comprising ribavirin or a derivative thereof effective against a Ljungan virus and pleconaril or a derivative thereof effective against a Ljungan virus and a kit relating to this composition. Further, a method is provided for treating Ljungan virus infection comprising administering ribavirin or a derivative thereof effective against the Ljungan virus as well as a composition and a kit comprising ribavirin.Type: ApplicationFiled: June 17, 2010Publication date: February 10, 2011Inventor: Bo Niklasson
-
Patent number: 7855277Abstract: A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects of the invention comprise a protein corresponding to a protein of the picornaviruses, antiserum or antibody directed against a protein of the picornaviruses, antigen comprising a protein of the picornaviruses, diagnostic kits, vaccines, use of the picornaviruses in medicaments, particularly for the treatment or prevention of Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, and Sudden Infant Death Syndrome, and methods of treatment of diseases caused by the picornaviruses.Type: GrantFiled: June 29, 2006Date of Patent: December 21, 2010Assignee: Apodemus ABInventor: Bo Niklasson
-
Patent number: 7803525Abstract: The present invention relates to a method for specifically detecting Ljungan virus (LV). In particular, the present invention relates to a method of detecting LV using quantitative real-time reverse transcriptase PCR. The present invention also provides kits for performing the method of the invention.Type: GrantFiled: March 15, 2006Date of Patent: September 28, 2010Assignees: Apodemus AB, Robert-Koch InstitutInventors: Bo Niklasson, Andreas Nitsche, Oliver Donoso Mantke, Matthias Niedrig
-
Patent number: 7560609Abstract: The invention relates to an animal model for diabetes and a method for obtaining said animal model. The invention also relates to the uses of the animal model for screening for or testing compounds for treating or preventing diabetes symptoms. The invention further relates to an assay for determining an individual's susceptibility to developing diabetes. The invention also relates to nucleic acid molecules isolated from Ljungan virus and to polypeptides encoded by any portion of said nucleic acid molecule.Type: GrantFiled: August 21, 2002Date of Patent: July 14, 2009Inventors: Bo Niklasson, Åke Lernmark
-
Publication number: 20090155769Abstract: The present invention relates to a method for specifically detecting Ljungan virus (LV). In particular, the present invention relates to a method of detecting LV using quantitative real-time reverse transcriptase PCR. The present invention also provides kits for performing the method of the invention.Type: ApplicationFiled: March 15, 2006Publication date: June 18, 2009Inventors: Bo Niklasson, Andreas Nitsche, Oliver Donoso Mantke, Matthias Niedrig
-
Publication number: 20090004143Abstract: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal.Type: ApplicationFiled: June 23, 2008Publication date: January 1, 2009Inventor: Bo Niklasson
-
Patent number: 7442380Abstract: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal.Type: GrantFiled: August 22, 2005Date of Patent: October 28, 2008Assignee: Apodemus ABInventor: Bo Niklasson
-
Publication number: 20070003573Abstract: (I) SEQ ID NO: 1 (Ljungan 87-012) AGTCTAGTCT TATCTTGTAT GTGTCCTGCA CTGAACTTGT TTCTGT CTCT 50? GGAGTGCTCT ACACTTCAGT AGGGGCTGTA CCCGGGCGGT CCCACT CTTC 100 ACAGGAATCT GCACAGGTGG CTTTCACCTC TGGACAGTGC ATTCCA CACC 150 CGCTCCACGG TAGAAGATGA TGTGTGTCTT TGCTTGTGAA AAGCTT GTGA 200 AAATCGTGTG TAGGCGTAGC GGCTACTTGA GTGCCAGCGG ATTACC CCTA 250 GTGGTAACAC TAGC A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (1) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease.Type: ApplicationFiled: June 7, 2006Publication date: January 4, 2007Inventor: Bo Niklasson
-
Publication number: 20070003574Abstract: A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects of the invention comprise a protein corresponding to a protein of the picornaviruses, antiserum or antibody directed against a protein of the picornaviruses, antigen comprising a protein of the picornaviruses, diagnostic kits, vaccines, use of the picornaviruses in medicaments, particularly for the treatment or prevention of Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, and Sudden Infant Death Syndrome, and methods of treatment of diseases caused by the picornaviruses.Type: ApplicationFiled: June 29, 2006Publication date: January 4, 2007Inventor: Bo Niklasson
-
Patent number: 7101554Abstract: A new group of picornaviruses is disclosed. The picornaviruses of the invention comprise in the non-coding region of their viral genome a nucleotide sequence which corresponds to cDNA sequence (I) or homologous sequences having at least 75% homology to the SEQ ID NO:1, and they cause mammalian disease. Further aspects of the invention comprise a protein corresponding to a protein of the picornaviruses, antiserum or antibody directed against a protein of the picornaviruses, antigen comprising a protein of the picornaviruses, diagnostic kits, vaccines, use of the picornaviruses in medicaments, particularly for the treatment or prevention of Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatique Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, and Sudden Infant Death Syndrome, and methods of treatment of diseases caused by the picornaviruses.Type: GrantFiled: September 9, 1997Date of Patent: September 5, 2006Assignee: Microtus ABInventor: Bo Niklasson
-
Publication number: 20060018876Abstract: A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barré Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyothrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden Infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal.Type: ApplicationFiled: August 22, 2005Publication date: January 26, 2006Inventor: Bo Niklasson
-
Publication number: 20050233311Abstract: The present invention relates to a new family of viruses within the Picornavirus family. The present invention also relates to an isolated nucleic acid from said virus or fragments of said nucleic acid. The present invention also relates to an isolated protein of said virus or an immunogenic fragment thereof. The invention also relates to antibodies or antigen-binding fragments of such antibodies directed against said virus. The present invention also relates to diagnostic kits. The present invention also relates to a method of detecting the presence of said virus in a subject suspected of having a viral infection.Type: ApplicationFiled: April 23, 2003Publication date: October 20, 2005Inventors: Michael Lindberg, Susanne Johansson, Bo Niklasson
-
Publication number: 20050043648Abstract: An epicutaneous test plaster, which is intended for removable adhesion to a skin portion of a person subjected to testing, has a flexible carrier (10) with a medical adhesive layer (12) and a number of test chambers (31). The test chambers contain a filter element (17) for absorption of allergen and are oriented with their opening directed away from the flexible carrier (10). A removable cover layer (27, 32) extends over all the test chambers and the carrier (10) and is removably secured to them by means of the adhesive layer (12) of the carrier. According to the invention, the test chambers (31) are formed as separate chambers, which are each separately fixed to the carrier and which are made up of a number of different sub-layers (13, 17, 19, 20, 24, 26).Type: ApplicationFiled: January 16, 2003Publication date: February 24, 2005Inventor: Bo Niklasson
-
Publication number: 20040265793Abstract: The invention relates to an animal model for diabetes and a method for obtaining said animal model. The invention also relates to the uses of the animal model for screening for or testing compounds for treating or preventing diabetes symptoms. The invention further relates to an assay for determining an individual's susceptibility to developing diabetes. The invention also relates to nucleic acid molecules isolated from Ljungan virus and to polypeptides encoded by any portion of said nucleic acid molecule.Type: ApplicationFiled: August 12, 2004Publication date: December 30, 2004Inventors: Bo Niklasson, Ake Lernmark